CLR 131 achieves 50% overall response rate in cohort 6 of pngoing phase 1 study
Cellectar Biosciences announced initial results from Cohort 6 in the Company’s ongoing Phase 1 clinical study with CLR 131 in Relapsed or Refractory Multiple Myeloma. The 37.5mCi/m2 fractionated dose was determined to be safe and tolerable by the independent DMC. May 15, 2019